Vertex Pharmaceuticals Inc. is a leading biopharmaceutical company headquartered in Boston, Massachusetts, specializing in the development of innovative therapies for serious diseases, primarily cystic fibrosis (CF). Renowned for its pioneering work in CF treatments, Vertex has made significant strides that have markedly improved patient outcomes. The company is not resting on its laurels; it is actively expanding its research and development efforts into new therapeutic areas, demonstrating a strong commitment to addressing unmet medical needs. With a solid financial foundation and a strategic focus on sustainable growth, Vertex is well-positioned to continue driving advancements in healthcare and delivering long-term value to its stakeholders. Show more

Location: 50 NORTHERN AVENUE, BOSTON, MA, UNITED STATES, 02210, Boston, MA, 02210, USA | Website: https://www.vrtx.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

120.5B

52 Wk Range

$362.50 - $519.68

Previous Close

$469.90

Open

$466.79

Volume

759,497

Day Range

$464.01 - $473.74

Enterprise Value

114.8B

Cash

4.94B

Avg Qtr Burn

N/A

Insider Ownership

0.17%

Institutional Own.

97.54%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ORKAMBI® (lumacaftor/ivacaftor) Details Cystic fibrosis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Details Cystic fibrosis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
JOURNAVX™ (suzetrigine) (VX-548) Details Pain, Acute pain	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALYFTREK (Vanza triple) (vanzacaftor/tezacaftor/deutivacaftor) Details Cystic fibrosis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) Details Cystic fibrosis (CF)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KALYDECO® (ivacaftor) Details Cystic fibrosis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CASGEVY™ (exagamglogene autotemcel) (exa-cel) (CTX001) Details Beta thalessemia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KALYDECO® (ivacaftor) Details Cystic fibrosis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CASGEVY™ (exagamglogene autotemcel) (exa-cel) (CTX001) Details Sickle cell disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Details Cystic fibrosis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
JOURNAVX™ (suzetrigine) (VX-548) Details Pain, Diabetic peripheral neuropathy	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Povetacicept Details IgA Nephropathy (IgAN)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Inaxaplin (VX-147) Details APOL1-Mediated Kidney Disease (AMKD)	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VX-993 Details Diabetic peripheral neuropathy (DPN)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VX-407 Details Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
JOURNAVX™ (suzetrigine) (VX-548) Details Pain, Lumbosacral radiculopathy	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Povetacicept Details IgA nephropathy, primary membranous nephropathy (pMN)	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VX-670 Details Myotonic Dystrophy Type 1 (DM1)	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VX-522 Details Cystic fibrosis	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zimislecel (VX-880) Details Type 1 diabetes	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VX-993 (IV formulation) Details Healthy volunteers	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VX-828 Details Cystic Fibrosis	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VX-993 Details Moderate-to-severe acute pain following bunionectomy surgery	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VX-264 Details Type 1 diabetes	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VX-864 Details Severe alpha-1 antitrypsin deficiency	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.